%0 Journal Article
%T Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
%A Em¨ªlia Sousa
%A Fernando Dur£¿es
%J Archive of "Pharmaceuticals".
%D 2019
%R 10.3390/ph12020063
%X Omadacycline (Nuzyra£¿) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria
%K Omadacycline
%K aminomethylcycline
%K tetracycline
%K antibacterial
%K protein synthesis inhibitor
%K FDA approved
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630996/